CompletedNCT04067375
Towards Routine HPA-screening In Pregnancy to Prevent FNAIT
Studying Fetal and neonatal alloimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Leiden University Medical Center
- Principal Investigator
- Dick Oepkes, Prof MD PhDDepartment of Obstetrics, Leiden University Medical Centre, Leiden
- Intervention
- Clinical data collection.(other)
- Enrollment
- 3660 enrolled
- Eligibility
- FEMALE
- Timeline
- 2017 – 2020
Study locations (1)
- Stichting Bloedbank Sanquin, Amsterdam, Netherlands
Collaborators
Sanquin Research & Blood Bank Divisions · Landsteiner Foundation for Blood Transfusion
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04067375 on ClinicalTrials.govOther trials for Fetal and neonatal alloimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06533098A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)Janssen Research & Development, LLC
- RECRUITINGPHASE3NCT06449651A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)Janssen Research & Development, LLC
- RECRUITINGNCT04598750The Neonatal Hemorrhagic Risk Assessment in ThrombocytopeniaKarolinska Institutet
See all trials for Fetal and neonatal alloimmune thrombocytopenia →